# A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer

> **NCT02407054** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 142 (actual)

## Conditions studied

- Prostate Cancer Metastatic

## Interventions

- **DRUG:** LY3023414
- **DRUG:** Enzalutamide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02407054
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-29
- **Primary completion:** 2018-09-26
- **Final completion:** 2020-04-16
- **Target enrollment:** 142 (ACTUAL)
- **Last updated:** 2021-05-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02407054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02407054, "A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02407054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*